Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Vaxil Bio Ltd VXLLF


Primary Symbol: V.VXL

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19... see more

TSXV:VXL - Post Discussion

Vaxil Bio Ltd > Some people can get vaccinated yesterday
View:
Post by TheWeakendz on Sep 29, 2021 9:10pm

Some people can get vaccinated yesterday

Unfortunately/sadly, some can't. Imo, covid might be controlled. I haven't heard of someone dying from a covid needle, just from having a needle. So oral might be late to the party, figure of speech. But I don't know all of the stats. After the last HALT, draw your own conclusions. I'm invested in BIOV. (what happened to blig, lol). Jmo. Do your DD. I hope you all get extremely lucky here. See ya??? Biov could be going after cancer???
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities